| Date Filed | Type | Description |
| 10/03/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 10% stake in Soleno Therapeutics, Inc. |
| 10/02/2023 |
4
| Carlyle Group Inc. (10% Owner) has filed a Form 4 on SOLENO THERAPEUTICS INC|
Txns:
| Converted 329,930 shares
@ $1.75, valued at
$577.4k
Converted 1,092,056 options to buy
@ $1.75, valued at
$1.9M
Converted 762,126 options to buy
@ $0.01, valued at
$7.6k
|
|
| 10/02/2023 |
3
| Redett John C. (CFO) has filed a Form 3 on Carlyle Group Inc. |
| 10/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/25/2023 |
4
| SCHWARTZ HARVEY M (CEO) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Granted 80,717 shares
@ $0 |
|
| 08/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/18/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 12.3% stake in Soleno Therapeutics, Inc. |
| 08/04/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/03/2023 |
4
| Finn Christopher (COO) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Sold 27,067 shares
@ $32.36, valued at
$875.9k
|
|
| 08/03/2023 |
4
| Buser Curtis L. (CFO) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Sold 25,828 shares
@ $32.36, valued at
$835.8k
|
|
| 08/03/2023 |
4
| Larson Bruce M. (Chief Human Resources Officer) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Sold 13,413 shares
@ $32.36, valued at
$434k
|
|
| 08/03/2023 |
4
| Andrews Charles Elliott Jr. (Chief Accounting Officer) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Sold 6,669 shares
@ $32.36, valued at
$215.8k
|
|
| 08/03/2023 |
4
| Ferguson Jeffrey W. (General Counsel) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Sold 11,939 shares
@ $32.36, valued at
$386.3k
|
|
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 4.2% stake in Vera Therapeutics, Inc. |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.1% stake in Carlyle Credit Income Fund |
| 07/05/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 5.5% stake in Vera Therapeutics, Inc. |
| 07/05/2023 |
4
| Carlyle Group Inc. (10% Owner) has filed a Form 4 on CommScope Holding Company, Inc.|
Txns:
| Acquired 15,337 convertible preferred
@ $0 |
|
| 06/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/05/2023 |
4
| Cherwoo Sharda (Director) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Granted 5,709 shares
@ $0 |
|
| 06/05/2023 |
3
| Cherwoo Sharda (Director) has filed a Form 3 on Carlyle Group Inc. |
| 06/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/25/2023 |
4
| SCHWARTZ HARVEY M (CEO) has filed a Form 4 on Carlyle Group Inc.|
Txns:
| Granted 85,723 shares
@ $0 |
|
| 05/10/2023 |
4
| Carlyle Group Inc. (10% Owner) has filed a Form 4 on MKS INSTRUMENTS INC|
Txns:
| Sold 2,000,000 shares
@ $86.125, valued at
$172.3M
|
|
| 05/10/2023 |
SC 13D/A
| Carlyle Group Inc. has filed a Schedule 13D for Soleno Therapeutics, Inc. |
| 05/10/2023 |
4
| Carlyle Group Inc. (10% Owner) has filed a Form 4 on SOLENO THERAPEUTICS INC|
Txns:
| Bought 1,092,056 options to buy
@ $1.75, valued at
$1.9M
Bought 1,778,000 options to buy
@ $2.5, valued at
$4.4M
|
|
| 05/09/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.2% stake in Reneo Pharmaceuticals, Inc. |
| 05/05/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
|